SYNGENE

52‑Week Range: ₹599.55 – ₹960.60 Market Capitalization: ₹27,400–₹27,444 crore P/B Ratio: 5.7× (Book value ≈ ₹117, reflecting BV per share) Dividend Yield: 0.18–0.19% (very low yield) Business Model: One of India’s largest CRO/CDMO providers with integrated capabilities in drug discovery and manufacturing. Serves >400 clients, including top global pharma players, operates R&D and manufacturing hubs in Bangalore, Hyderabad, Mangalore